Q-omics provides the consensus-scored RPL21P31 profile across patient tissues and cancer cell-line models. RPL21P31 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, RPL21P31 is differentially expressed in 4, with the highest sampling consensus in LUAD. Additionally, RPL21P31 RNA expression shows 5,554 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRP, LUAD, and STAD as cancer lineages where RPL21P31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL21P31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL21P31 survival associations across molecular data types. RPL21P31 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL21P31 RNA expression–survival associations across cancer types. High RPL21P31 expression shows unfavorable associations in KIRP, MESO, DLBC and UCS, but favorable associations in GBM and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRP as the clearest survival context for RPL21P31 RNA expression.
This table summarizes RPL21P31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL21P31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL21P31 shows lower tumor expression in THCA and higher tumor expression in LUAD, HNSC and BRCA. The LUAD box plot shows higher RPL21P31 RNA expression in tumor versus normal tissue (log2 FC = +0.088, t-test p = .016).
This table shows molecular features associated with RPL21P31 in patient tissues and cancer cell lines. In patient samples, RPL21P31 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
